What to do when a claimant's medication list includes over-the-counter supplements
Managing complementary medicines and OTC supplements in insurance medication funding decisions
Published: 3 April 2026 | Updated: 3 April 2026
Why this matters
You've received a claim for supplementation. The claimant is taking fish oil, magnesium, turmeric, CoQ10, or a dozen other over-the-counter products to manage pain, support recovery, or fill perceived nutritional gaps. The question isn't whether they work (that's complicated), but whether your scheme should fund them. This is part funding decision, part evidence question, part causation analysis.
The bottom line: not all supplements are created equal, and your scheme's responsibility isn't to subsidize all health spending, just injury-related treatment.
Understanding the OTC supplement landscape
Before you decide anything, understand what you're dealing with:
- Supplements are not medicines: In Australia, supplements are regulated by the TGA under different frameworks than medicines. This means less stringent efficacy testing, lower evidence standards, and different safety requirements
- Evidence quality varies dramatically: Some supplements have reasonable evidence for specific uses (e.g., omega-3 fatty acids for some inflammatory conditions). Others have minimal evidence (e.g., collagen for joint health)
- Safety is not guaranteed: "Natural" doesn't mean safe. Some supplements interact with prescription medications, affect clotting, or cause direct adverse effects
- Cost varies widely: Some claimants spend hundreds per month on complementary products. Without evidence, this becomes expensive placebo
- Prescriber involvement varies: Some supplements are recommended by doctors, others are self-selected by claimants based on Internet advice or naturopaths
Your position: You're not obligated to fund unproven supplements. You're also not obligated to exclude supplements with reasonable evidence for injury-related conditions. Your decision should rest on evidence and causation, not ideology for or against complementary medicine.
The assessment framework
1. Is the supplement causally related to the injury?
This is your starting point. The claimant was injured. They were prescribed (or self-prescribed) a supplement. Is there a causal link between the injury and the supplement use? If the claimant had arthritis before the injury and is now taking glucosamine for generalized joint health, that's not injury-specific. If they developed a specific pain condition from the injury and are taking targeted supplementation for that condition, the causal link is clearer.
2. Is there evidence that this supplement helps with the claimed condition?
Not "do some people say it helps." Do clinical trials or systematic reviews show benefit? For pain conditions, does evidence support pain reduction? For inflammation, does it reduce inflammatory markers? Be specific. Some supplements have evidence for specific indications; some have none. Ask your pharmacist if you're unsure.
3. Is the supplement prescribed or recommended by a healthcare provider?
Doctor or physiotherapist recommendation carries different weight than self-selection from a health food store. Healthcare provider involvement suggests the supplement is part of a clinical plan, not just wishful thinking. This isn't a deal-breaker if the supplement isn't recommended, but it's a consideration.
4. What is the cost, and is it proportionate to the benefit?
Some claimants spend hundreds per month on multiple supplements with minimal individual evidence. This is expensive preventative healthcare that your scheme isn't obligated to fund. Others spend modest amounts on one or two items with reasonable evidence. Cost proportionality matters.
5. Are there safety concerns or interactions?
Some supplements interact with prescription medications, increase bleeding risk, or have direct adverse effects. A claimant on warfarin taking garlic or ginkgo is at risk. A claimant on metformin taking chromium is taking substances that interact with their medications. Safety overrides cost considerations.
6. Is there an alternative prescription medication that would serve the same purpose at lower cost or better evidence?
For some conditions, prescription medications have superior evidence. If a claimant could take a PBS-listed analgesic or anti-inflammatory instead of purchasing expensive complementary products, cost-effectiveness favors the prescription option. This is a legitimate consideration for scheme funding decisions.
Common supplement scenarios
Scenario A: Fish oil for inflammation post-injury
Evidence status: Moderate. Omega-3 fatty acids have some evidence for inflammation and may help certain pain conditions, though efficacy is modest.
Causation: Clear. The claimant developed an inflammatory condition from the injury.
Cost: Typically AUD 20-40 per month.
Your call: This is defensible. There's a causal link, reasonable evidence exists, cost is modest, and healthcare provider often recommends it. This is a reasonable claim to fund as part of injury-related pain management.
Scenario B: Collagen supplementation for joint health
Evidence status: Weak. Some marketing claims; limited clinical trial support for joint health. More marketing than medicine.
Causation: Plausible but indirect. The claimant has a joint injury and is taking it for general joint support.
Cost: Often AUD 50-100+ per month.
Your call: Weak evidence combined with high cost and lack of healthcare provider recommendation. This is borderline or decline. If the claimant is already funding it, don't actively pay for it. If they want you to, request healthcare provider recommendation and clinical justification. Otherwise, this is elective preventative supplementation, not injury treatment.
Scenario C: Magnesium for muscle tension
Evidence status: Mixed. Some evidence for muscle cramps; less clear for general muscle tension or recovery.
Causation: Reasonable. The claimant has injury-related muscle tension.
Cost: Typically AUD 15-30 per month.
Your call: Low cost, reasonable causation, modest evidence. This is acceptable to fund if recommended by a healthcare provider. If the claimant is self-selecting, it's less compelling, but cost is low enough that it's not worth significant dispute. Focus your scrutiny on high-cost items.
Scenario D: Multi-vitamin for "general wellness"
Evidence status: Weak. No strong evidence that multivitamins improve general wellness in non-deficient populations.
Causation: Weak. The claimant isn't deficient in anything documented; this is preventative.
Cost: AUD 20-50 per month.
Your call: Decline. This isn't injury-related, there's no evidence it helps, and it's not a standard part of injury treatment. This is the claimant choosing to fund general health, not a consequence of the injury.
Scenario E: Multiple high-cost supplements (AUD 200+ per month total)
Evidence status: Variable, but often weak when multiple items are combined.
Causation: Speculative. The claimant has become focused on supplementation as recovery strategy.
Cost: Significant burden on the claim.
Your call: Refer for a medication review. When multiple supplements accumulate, there's often duplication, weak evidence bases, or interaction concerns. A pharmacist can audit the supplement regimen, identify redundancy, remove items without evidence, and focus on items with defensible benefit. This typically reduces costs significantly.
Documentation you should request
Before approving supplement funding, request:
- A list of all supplements, doses, and duration of use
- A healthcare provider's recommendation for each supplement (not self-selection)
- The clinical rationale for why each supplement is needed for the injury condition
- Total monthly cost for all supplements
- Any documented deficiencies or conditions the supplement is addressing (e.g., iron deficiency, documented vitamin D insufficiency)
- Information on any prescriptions the supplement might interact with
Decision rules for supplement funding
- Fund: Healthcare provider recommended, injury-related, moderate evidence, reasonable cost, no safety concerns
- Conditional fund: Self-selected but low-cost, some evidence, and no safety risks; or high-cost with strong evidence
- Refer for review: Multiple supplements, high total cost, unclear rationale, or potential interactions
- Decline: Weak evidence, no healthcare provider involvement, high cost, or no clear injury causation
| Supplement | Typical Evidence | Injury-Related Use? | Funding Decision |
|---|---|---|---|
| Fish oil (omega-3) | Moderate (inflammation, some pain) | Yes (post-inflammatory injury) | Fund if healthcare provider recommended |
| Magnesium | Weak to moderate (muscle cramps) | Yes (muscle-related injury) | Fund if low-cost; healthcare provider helpful |
| Vitamin D | Strong (if deficient) | Yes (if documented deficiency) | Fund if deficiency documented; test first |
| Collagen | Weak (joint health) | Maybe (if joint injury) | Decline unless healthcare provider recommends and high-level evidence provided |
| Turmeric/curcumin | Weak to moderate (inflammation) | Yes (post-inflammatory injury) | Fund if low-cost and healthcare provider involved; check interactions |
| Multi-vitamin | Weak (general wellness) | No (preventative) | Decline |
| Probiotics | Weak (gut health) | No (unless GI condition post-injury) | Decline unless GI condition documented |
Red flags for supplement review
Refer for a medication review if you notice:
- Total supplement cost exceeding AUD 150 per month
- Claimant taking 5+ different supplements without clear rationale
- Supplements recommended by non-healthcare providers (naturopaths, health food store staff)
- Supplements with potential interactions with prescription medications
- Claimant has become focused on supplementation as primary treatment strategy, delaying evidence-based therapies
- Supplement regimen changing frequently without clear clinical reason
What you should communicate to claimants
If you're declining supplement funding, explain it clearly:
- "This supplement doesn't have strong clinical evidence for your condition, and we fund treatments based on evidence. If your healthcare provider believes this is important, please ask them to explain the clinical basis."
- "This is preventative health spending, not injury-related treatment. Your scheme funds treatment of the injury and its direct consequences, not general wellness products."
- "The cost of this supplement is high, and the evidence of benefit is limited. We've approved [alternative] which has better evidence and lower cost."
Key takeaways
- Supplements aren't automatically excluded from funding, nor automatically included
- Evaluate each supplement on evidence, causation, cost, and safety
- Healthcare provider involvement strengthens the case for funding
- High-cost, low-evidence supplement regimens warrant a pharmacist review
- Your scheme funds injury treatment, not general health or prevention
- Document your decisions for consistency and defensibility
Drowning in supplement claims?
IMM pharmacists review supplement regimens, audit cost-effectiveness, identify redundancy, and recommend which supplements to fund and which to decline. We provide evidence-based guidance that protects your scheme while supporting claimant health.
Request a Medication Review
